FY24 거래 및 FY25 전망 업데이트
16 4월 2024
닥터마틴 PLC
FY24 in line with expectations and update on FY25 outlook
24회계연도 실적
Dr. Martens Plc (the Company) will announce its FY24 results on 30th May, with results expected to be in line with guidance and consensus expectations.
As expected, we saw a pick-up in Direct to Consumer ("DTC") in Q4, to high single-digit year-on-year growth, compared with a 3% decline in Q3 (all on constant currency terms). This was as a result of good growth across EMEA, a flat outcome in the USA and a very strong result in APAC, led by Japan. Q4 Group wholesale performed in line with our expectations.
FY25 planning assumptions
As we start the new financial year, the Board is taking a prudent view and would like to share with investors our planning assumptions:
· USA wholesale revenue is anticipated to be double-digit down year-on-year. We have recently finalised the Autumn/Winter order book, which makes up the majority of the second half of USA wholesale, and this is significantly down year-on-year. If wholesale customers become more optimistic, we could see in-season re-orders, however these are hard to predict. Given the nature of wholesale orders, the full benefit of any restock always has a lag into the following season. The decline in wholesale has a significant impact on profitability, with a base assumption being in the region of a £20m PBT impact year-on-year, assuming no meaningful in-season re-orders.
· We are seeing single-digit inflation in our cost base, and also intend to invest in retaining and incentivising talent throughout the organisation; together these equate to a year-on-year PBT headwind in the region of £35m. As previously communicated, we do not anticipate increasing prices further this year, and therefore in FY25 we are unable to offset cost inflation as we have in prior years.
· Given the ongoing challenging performance of our USA wholesale business, we expect to continue to require the additional inventory storage facilities in this market through FY25, and therefore the majority of the £15m of additional costs incurred in FY24 are expected to repeat in FY25.
· As previously communicated, we have a number of important investment projects underway, incurring operating costs in addition to capital expenditure, including our new Supply and Demand Planning system and Customer Data Platform. These projects are progressing well and will deliver benefits in outer years. We also continue to invest in brand marketing to drive future growth.
There is a wide range of potential outcomes for FY25 given that we have only recently started the year. However, we have assumed that revenue declines by single-digit percentage year-on-year and at the PBT level we could see a worst-case scenario of PBT of around one-third of the FY24 level. There are also scenarios where the profit outturn could be significantly better than this, with the key factor being if USA performance is stronger than our planning assumptions as we progress through the year. We will also look to drive cost savings wherever possible, whilst protecting our brand and future growth opportunities. Against this backdrop, we are focused on cash generation and have already significantly reduced purchases from the supply chain, which will underpin the strength of the balance sheet.
Our business is always second half weighted, however this year, given the phasing of USA wholesale and costs, this will particularly be the case.
Kenny Wilson, CEO, said, "The FY25 outlook is challenging, and the whole organisation is focused on our action plan to reignite boots demand, particularly in the USA, our largest market. The nature of USA wholesale is that when customers gain confidence in the market we will see a significant improvement in our business performance, but we are not assuming that this occurs in FY25.
"We have built an operating cost base in anticipation of a larger business, however with revenues weaker we are currently seeing significant deleverage through to earnings. Against this backdrop, we will be laser-focused on driving cost efficiencies where possible. We also have a number of ongoing investment projects which will deliver results in outer years. We continue to believe in our DTC-first strategy and the considerable headroom for growth. Our brand remains strong, and we have a compelling product pipeline. These all give us confidence as we look beyond this transition year into future years."
문의
투자자 및 분석가
Bethany Barnes, 투자자 관계 이사 [이메일 보호] +44 7825 187465
Beth Callum, Investor Relations Manager [이메일 보호] +44 203 995 2644
PR 기사
H/Advisors Maitland +44 207 379 5151
Katharine Spence +44 7384 535739
Gill Hammond, Director of Communications +44 7384 214248
닥터마틴 소개
Dr. Martens는 1960년 Northamptonshire에서 설립된 영국의 상징적인 브랜드입니다. 원래 튼튼하고 내구성이 뛰어난 부츠를 찾는 근로자를 위해 제작된 이 브랜드는 다양한 청소년 하위 문화 및 관련 음악 운동에 빠르게 채택되었습니다. Dr. Martens는 그 이후로 노동계급의 뿌리를 초월하면서도 여전히 자랑스러운 유산을 기념하고 있으며, 250년 후 "Docs" 또는 "DM's"는 권한 부여의 상징과 그들 자신의 태도로 사용하는 전 세계 사람들이 착용합니다. . 회사는 FTSE XNUMX 지수의 구성종목입니다.
RNS는 귀하의 IP 주소를 사용하여 약관 준수 여부를 확인하고, 귀하가 이 커뮤니케이션에 포함된 정보를 사용하는 방식을 분석하고, 그러한 분석을 익명으로 다른 사람과 상용 서비스의 일부로 공유할 수 있습니다. RNS와 런던 증권 거래소가 귀하가 제공한 개인 데이터를 사용하는 방법에 대한 자세한 내용은 개인 정보 보호 정책을 참조하십시오.